Finerenone

Finerenone is a nonsteroidal antimineralocorticoid that is in phase III clinical trials for the treatment of chronic kidney disease in people with type II diabetes as of October 2015. It has less relative affinity to other steroid hormone receptors than currently available antimineralocorticoids such as eplerenone and spironolactone, which should result in fewer adverse effects like gynaecomastia, impotence, and low libido.

Read more in the app

Finerenone in patients with chronic kidney disease due to glomerular diseases - EurekAlert!

Finerenone slows kidney function decline and reduces cardiovascular-kidney risk in non-diabetic chronic kidney disease, major trial shows - EurekAlert!

Finerenone and atrial fibrillation in heart failure - EurekAlert!

Clinical trial finds finerenone reduces worsening heart failure and cardiovascular death

Finerenone improves outcomes in patients with mild-to-moderate kidney disease and diabetes

Finerenone may delay onset of AFib in patients with chronic kidney disease, diabetes